Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care
about
Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling studyEfficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sitesInter-relationships of cardinal features and outcomes of symptomatic pediatric Plasmodium falciparum MALARIA in 1,933 children in Kampala, Uganda.Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.The impact of anthelmintic treatment intervention on malaria infection and anaemia in school and preschool children in Magu district, Tanzania: an open label randomised intervention trial.Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccineSevere malaria in children leads to a significant impairment of transitory otoacoustic emissions--a prospective multicenter cohort study.Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions.Development of an Immunosensor for PfHRP 2 as a Biomarker for Malaria DetectionThe Ethics of Health Care Delivery in a Pediatric Malaria Vaccine Trial: The Perspectives of Stakeholders From Ghana and Tanzania.The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.Le vaccin antipaludique RTS,S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination
P2860
Q28397448-E1538654-C786-4C00-9BE8-60836BDE7F3BQ28541281-716273F8-89C8-4666-A908-EC2449F09BF0Q33405551-BEA2DCF3-0CC4-4A1C-B5C1-86959F0DCC8EQ35198729-E5F742E6-2DA0-4C4A-B7D1-8267283668C6Q35337417-E2C74E52-41D0-4B1B-8DFC-12F905959D0DQ35428630-82E04AF6-9C37-40F2-BD5D-FC73199C1155Q35563056-4377E1F9-226F-49D3-A011-31EB02F4EBE4Q35645341-DF223873-7D5F-4682-8C87-0500B86AC39FQ38059751-D0E07525-CF38-4DF9-9B8D-BD9693CE94C4Q41663710-C275FB05-B0D6-4B1E-BA54-0E937411F66CQ46190745-1CB7A8F8-C7D0-4924-A420-8A31A2E52656Q47977891-23407B1B-EF14-45D6-9B04-2C83A915A755Q58131059-2C18E318-3374-4DBF-96C3-F04AE3E0D64E
P2860
Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Assessment of severe malaria i ...... ta collection and patient care
@ast
Assessment of severe malaria i ...... ta collection and patient care
@en
type
label
Assessment of severe malaria i ...... ta collection and patient care
@ast
Assessment of severe malaria i ...... ta collection and patient care
@en
prefLabel
Assessment of severe malaria i ...... ta collection and patient care
@ast
Assessment of severe malaria i ...... ta collection and patient care
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Assessment of severe malaria i ...... ta collection and patient care
@en
P2093
Amanda Leach
Clinical Trials Partnership Committee
David Schellenberg
Jahit Sacarlal
Jennifer Evans
Johan Vekemans
Kwaku Poku Asante
Mary J Hamel
Nahya Salim
Patricia Njuguna
P2860
P2888
P356
10.1186/1475-2875-10-221
P577
2011-08-04T00:00:00Z
P5875
P6179
1048151031